Details

Autor(en) / Beteiligte

• Wang, Shouzheng
• Li, Zefu
• Wang, Yunbing
• Zhao, Tianli
• Mo, Xuming
• Fan, Taibing
• Li, Jianhua
• You, Tao
• Deng, Rundi
• Ouyang, Wenbin
• Wang, Weiwei
• Zhang, Chuangnian
• Butera, Gianfranco
• Hijazi, Ziyad M.
• Pang, Kunjing
• Zhu, Da
• Jiang, Shiliang
• Zhang, Gejun
• Hu, Xiaopeng
• Xie, Yongquan
• Zhang, Fengwen
• Fang, Fang
• Sun, Jingping
• Li, Ping
• Chen, Juan
• Luo, Zhiling
• Pan, Xiangbin

Titel

Transcatheter closure of perimembranous ventricular septal defect using a novel fully bioabsorbable occluder: multicenter randomized controlled trial

Ist Teil von

• Science bulletin, 2023-05, Vol.68 (10), p.1051-1059

Ort / Verlag

Netherlands: Elsevier B.V

Erscheinungsjahr

2023

Link zum Volltext

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• [Display omitted] Although the use of bioabsorbable occluder is expected to reduce the risk of metal occluder-related complications, it has not been approved due to incomplete degradation and new complications. Novel fully bioabsorbable occluders were designed to overcome such limitations. The aim of this study was to investigate the efficacy and safety of a fully biodegradable occluder in patients with ventricular septal defects. 125 patients with perimembranous ventricular septal defect (VSD) larger than 3 mm were screened from April 2019 to January 2020 in seven centers. 108 patients were enrolled and randomized into the bioabsorbable occluder group (n = 54 patients) and nitinol occluder group (n = 54). A non-inferiority design was utilized and all patients underwent transcatheter device occlusion. Outcomes were analyzed with a 24-month follow-up. All patients were successfully implanted and completed the trial. No residual shunt >2 mm was observed during follow-up. Transthoracic echocardiography showed a hyperechoic area corresponding to the bioabsorbable occluder which decreased primarily during the first year after implantation and disappeared within 24 months. Postprocedural arrhythmia was the only occluder-related complication with an incidence of 5.56% and 14.81% for the bioabsorbable and nitinol groups, respectively (P = 0.112). The incidence of sustained conduction block was lower in the bioabsorbable occluder group (0/54 vs. 6/54, P = 0.036) at 24-month follow-up. In conclusion, the novel fully bioabsorbable occluder can be successfully and safely implanted under echocardiography guidance and reduce the incidence of sustained postprocedural arrythmia. The efficacy and safety of this fully biodegradable occluder are non-inferior to that of a traditional nitinol one.